Dynamic Technology Lab Private Ltd Increases Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Dynamic Technology Lab Private Ltd increased its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 77.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,900 shares of the company’s stock after purchasing an additional 13,893 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Vir Biotechnology were worth $239,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in VIR. Vanguard Group Inc. raised its holdings in Vir Biotechnology by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock worth $125,362,000 after purchasing an additional 78,216 shares in the last quarter. Tidal Investments LLC bought a new position in shares of Vir Biotechnology during the 1st quarter worth approximately $352,000. Louisiana State Employees Retirement System lifted its position in Vir Biotechnology by 2.8% during the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock valued at $390,000 after acquiring an additional 1,200 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Vir Biotechnology by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock valued at $7,238,000 after acquiring an additional 6,359 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Vir Biotechnology by 15.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock valued at $219,000 after acquiring an additional 3,215 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Insiders Place Their Bets

In other news, Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the sale, the director now owns 11,616 shares in the company, valued at $90,604.80. This represents a 51.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 15,940 shares of company stock valued at $127,410. 15.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on VIR shares. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays decreased their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $36.40.

Vir Biotechnology Price Performance

NASDAQ VIR opened at $7.96 on Monday. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -2.03 and a beta of 0.46. The stock’s fifty day moving average price is $7.90 and its 200 day moving average price is $8.78. Vir Biotechnology, Inc. has a 1 year low of $6.56 and a 1 year high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The firm had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.22) earnings per share. Research analysts expect that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).